Vitamin B12 Medication-Driven Changes: What Depletes It, What Raises It, and What to Do

Why Medications Change Your Vitamin B12 Level

Vitamin B12 is absorbed through a precisely sequenced process: gastric acid releases it from food protein, intrinsic factor (produced by gastric parietal cells) binds free B12, and the complex is absorbed in the terminal ileum. Any drug that interferes with acid secretion, intrinsic factor availability, or ileal transport can reduce net absorption over time. Certain drugs also increase renal excretion or alter the enterohepatic recirculation of B12.

The clinical stakes are high. B12 is required for myelin synthesis, one-carbon metabolism, and DNA methylation. A sustained deficit below 300 pg/mL correlates with elevated homocysteine, accelerated cognitive decline, and peripheral neuropathy that may be irreversible once symptoms appear.

The Problem With Standard Reference Ranges

Most commercial labs flag B12 as "low" only below 200 pg/mL. That threshold was set to capture overt megaloblastic anemia, not subclinical neurological injury. A 2016 systematic review in the Annals of Clinical Biochemistry found that neuropsychiatric symptoms can appear at levels between 200 and 400 pg/mL, a zone most labs report as normal [1]. Clinicians practicing precision or longevity medicine therefore use a functional lower boundary of 400 pg/mL and an optimum of 600 to 1,000 pg/mL.

Confirming True Depletion With Functional Markers

Serum B12 alone misses about 30% of functional deficiencies because the assay measures total cobalamin, including inactive analogs. Adding methylmalonic acid (MMA) and total homocysteine closes that gap. MMA rises within weeks of cellular B12 insufficiency, before serum B12 falls below the lab's reference range. The 2019 European Federation of Neurological Societies guideline recommends MMA as the preferred confirmatory test when serum B12 is between 150 and 400 pg/mL [2].

Metformin: The Most Studied Drug Cause of B12 Depletion

Metformin lowers B12 by blocking calcium-dependent membrane action in the terminal ileum, which is required for the intrinsic factor-B12 receptor complex (cubam) to complete absorption. The effect is dose-dependent and cumulative over years, not a sudden drop.

What the Evidence Shows

The landmark UK Prospective Diabetes Study extension and, more recently, the TROMSO study (N=2,712) documented that patients on metformin for more than 5 years had a 26% lower median serum B12 compared with non-users [3]. The DPPOS (Diabetes Prevention Program Outcomes Study) followed 2,155 participants for up to 13 years and found that 19.1% of metformin users developed biochemical B12 deficiency versus 9.5% of placebo recipients (P<0.001) [4].

The American Diabetes Association 2024 Standards of Care state: "Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially those with peripheral neuropathy or anemia" [5].

Who Is at Highest Risk

Risk scales with daily dose and duration. Patients taking 2,000 mg/day for more than 4 years carry roughly 3-fold higher odds of deficiency compared with those on 500 mg/day for less than 1 year. Concurrent proton pump inhibitor use, older age, and vegan diet each add independent risk.

Monitoring and Repletion Protocol

The ADA recommends checking B12 at least once per year in all metformin users [5]. If serum B12 falls below 400 pg/mL or MMA is elevated, oral cyanocobalamin 1,000 mcg daily or sublingual methylcobalamin 1,000 mcg daily are both effective. A 2021 randomized trial (N=120) showed sublingual methylcobalamin 1,000 mcg/day normalized MMA in 94% of metformin-depleted patients within 12 weeks [6]. Calcium carbonate 1,200 mg with meals may also partially restore ileal absorption in metformin users, though the benefit is modest compared with direct supplementation.

Proton Pump Inhibitors and H2 Blockers

PPIs suppress gastric acid so thoroughly that pepsin cannot cleave B12 from dietary protein, leaving it bound and unabsorbable. Unlike metformin, PPIs do not block intrinsic factor itself, so crystalline B12 in supplements (which does not require acid for release) remains absorbable. The clinical consequence is that PPI-related depletion is almost entirely preventable with correct supplement formulation.

Epidemiological Scale

A Kaiser Permanente case-control study (N=25,956) published in JAMA found that patients who used PPIs for more than 2 years had a 65% higher risk of B12 deficiency compared with non-users (OR 1.65, 95% CI 1.58 to 1.73) [7]. H2 receptor antagonists produced a smaller but still significant increase (OR 1.25).

Practical Correction

Switching from food-bound to crystalline supplemental B12 bypasses the acid-dependency step entirely. Patients on long-term PPIs who take a 500 to 1,000 mcg oral cyanocobalamin tablet daily maintain normal serum B12 in most published series. Patients who cannot swallow tablets reliably, or who have atrophic gastritis, benefit from sublingual or intramuscular routes.

Other Medications That Lower B12

Nitrous Oxide

Nitrous oxide irreversibly oxidizes the cobalt center of B12, inactivating methionine synthase within hours of exposure. A single prolonged anesthetic exposure can precipitate acute B12 deficiency in a patient who is borderline-depleted. Patients on metformin or PPIs should have B12 confirmed above 400 pg/mL before elective procedures using nitrous oxide.

Colchicine and Cholestyramine

Colchicine at therapeutic doses (0.6 to 1.2 mg/day for gout) impairs ileal B12 absorption by disrupting microtubule-dependent membrane trafficking. Cholestyramine binds bile acids and may also reduce B12 enterohepatic recirculation. The magnitude of depletion from these agents is smaller than from metformin but cumulative in polypharmacy patients.

Anticonvulsants

Phenytoin, phenobarbital, and valproate have each been associated with lower B12 in observational cohorts. The proposed mechanisms include accelerated hepatic catabolism and reduced intrinsic factor secretion. A meta-analysis of 14 studies (N=1,042) found a mean B12 reduction of 68 pg/mL in patients on anticonvulsant monotherapy compared with age-matched controls [8].

Medications That Can Falsely Raise B12

Not all drug-related B12 changes reflect true repletion. Certain conditions and drugs push serum B12 up without improving cellular sufficiency.

Hepatic Disease and Myeloproliferative Disorders

The liver stores roughly 1,000 to 2,000 mcg of B12. Hepatocellular injury (from alcohol, NAFLD, or drug-induced hepatitis) releases stored B12 into the bloodstream, elevating serum levels while cellular reserves may actually be falling. A patient with an unexpectedly high serum B12 and no recent supplementation warrants liver function testing.

High-Dose Biotin Supplementation

Biotin at doses above 5,000 mcg/day (a common dose in hair and nail supplements) cross-reacts with several immunoassay platforms and can produce falsely elevated B12 results. The FDA issued a safety communication on biotin interference in laboratory assays in 2019 [9]. Patients should stop biotin for at least 48 hours before any B12 draw.

Interpreting Your B12 Lab Result: A Clinical Framework

Serum B12 results fall into four actionable zones when evaluated alongside clinical context and functional markers:

| Serum B12 (pg/mL) | Interpretation | Recommended Action | |---|---|---| | Below 200 | Overt deficiency | Intramuscular cyanocobalamin 1,000 mcg/day x 7 days, then monthly; neurology referral if symptomatic | | 200 to 399 | Subclinical / functional depletion likely | Check MMA and homocysteine; start oral or sublingual 1,000 mcg/day if MMA elevated | | 400 to 599 | Borderline; recheck in 6 months | Review medication list; optimize diet; consider low-dose supplementation | | 600 to 1,000 | Functional optimum | Maintain; recheck annually | | Above 1,000 (unsupplemented) | Investigate secondary cause | Check LFTs, CBC with differential; rule out myeloproliferative disease |

Patients on metformin, PPIs, H2 blockers, colchicine, or anticonvulsants should be evaluated at the more conservative 400 pg/mL lower threshold rather than waiting for the lab's standard flag.

Repletion Options: Forms, Doses, and Routes

Oral Cyanocobalamin

The most studied and least expensive form. A dose of 1,000 mcg/day by the oral route achieves adequate absorption even in the absence of intrinsic factor, because approximately 1% of a high oral dose is absorbed by passive diffusion across the gut mucosa. A Cochrane review (2018) found that high-dose oral B12 was as effective as intramuscular injection for normalizing serum B12 and MMA in most deficiency states [10].

Methylcobalamin

Methylcobalamin is the active coenzyme form used directly in methionine synthase. Some clinicians prefer it for patients with MTHFR variants or neurological symptoms, though head-to-head trials comparing methylcobalamin with cyanocobalamin show similar biochemical outcomes at equivalent doses. The practical advantage of sublingual methylcobalamin is convenience for patients who will not reliably swallow daily tablets.

Intramuscular Injection

Intramuscular cyanocobalamin 1,000 mcg bypasses all absorption barriers entirely and is the standard of care for pernicious anemia (autoimmune destruction of intrinsic factor-secreting cells) and for patients with terminal ileal disease or surgical resection. Loading regimens typically involve daily injections for 1 week, followed by monthly maintenance.

Dietary Sources

Animal products supply virtually all dietary B12. Beef liver delivers approximately 70 mcg per 3-oz serving. Salmon provides about 4.9 mcg per 3-oz serving. Eggs and dairy contribute smaller amounts. Strict vegans have essentially zero dietary B12 intake and require supplementation regardless of medication use.

Neurological and Cognitive Consequences of Chronic Depletion

B12 deficiency produces a spectrum of neurological damage, from mild cognitive slowing to irreversible subacute combined degeneration of the spinal cord. The dorsal and lateral columns of the thoracic spinal cord are most vulnerable because myelin synthesis requires the B12-dependent methionine synthase reaction.

Early symptoms include paresthesias (tingling or numbness in the hands and feet), gait instability, and short-term memory lapses. Serum B12 below 300 pg/mL is associated with a 2-fold higher rate of accelerated brain atrophy on MRI in adults over 60 years of age, according to a 5-year Oxford study (N=107) [11].

Recovery depends on how long the deficiency has persisted. Deficiency of less than 6 months typically resolves fully with repletion. Beyond 12 to 18 months of symptomatic deficiency, residual neurological deficit is common even after biochemical normalization. This timeline is why annual monitoring in high-risk medication users matters far more than waiting for symptoms to appear.

B12, Homocysteine, and Cardiovascular Risk

Insufficient B12 stalls the remethylation of homocysteine to methionine, causing homocysteine to accumulate. Elevated total homocysteine above 15 micromol/L is an independent risk factor for atherosclerosis, venous thromboembolism, and dementia. B12 supplementation alone, or combined with folate and B6, lowers homocysteine by 20 to 30% in most deficient patients.

The NORVIT trial and HOPE-2 trial tested whether B-vitamin supplementation that lowered homocysteine reduced cardiovascular events. Neither trial showed a benefit in patients without pre-existing B12 deficiency, suggesting that homocysteine reduction matters when it corrects a true deficit rather than when it is imposed on patients who are already replete [12].

Special Populations: GLP-1 Receptor Agonist Users

Patients using semaglutide, tirzepatide, or liraglutide for type 2 diabetes or weight management often also take metformin as background therapy. Rapid caloric restriction from appetite suppression can reduce dietary B12 intake at the same time that metformin is depleting absorptive capacity. Baseline B12 before starting a GLP-1 agent and a recheck at 6 months is a practical addition to the standard metabolic panel in this population.